Amylin, Lilly Wrap Up Diabetes Drug Alliance, Lawsuit

Law360, New York (November 8, 2011, 7:13 PM EST) -- Amylin Pharmaceuticals Inc. said Tuesday that it would pay Eli Lilly & Co. $250 million now and up to $1.2 billion later to end a lucrative diabetes drug joint marketing agreement that spurred contentious antitrust litigation between the two drugmakers.

San Diego-based Amylin — which teamed up with Indianapolis-based Eli Lilly in 2002 to develop a multimillion-dollar sales strategy to bring Type 2 diabetes drug Byetta, also known as exenatide, to market — alleged that Eli Lilly had violated the agreement when it announced earlier this...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.